Everolimus as first line therapy for pancreatic neuroendocrine tumours: current knowledge and future perspectives

[1]  J. Berlin,et al.  Phase 3 Trial of 177Lu‐Dotatate for Midgut Neuroendocrine Tumors , 2017, The New England journal of medicine.

[2]  C. Lu,et al.  The efficacy and safety of everolimus for the treatment of progressive gastroenteropancreatic neuroendocrine tumors: A multi‐institution observational study in Taiwan , 2016, Asia-Pacific journal of clinical oncology.

[3]  M. Falconi,et al.  mTOR inhibitors response and mTOR pathway in pancreatic neuroendocrine tumors. , 2016, Endocrine-related cancer.

[4]  A. Faggiano,et al.  Efficacy and Safety of Everolimus in Extrapancreatic Neuroendocrine Tumor: A Comprehensive Review of Literature. , 2016, The oncologist.

[5]  V. Hervieu,et al.  Prediction of response to everolimus in neuroendocrine tumors: evaluation of clinical, biological and histological factors , 2016, Investigational New Drugs.

[6]  G. Mortier,et al.  Long-term acquired everolimus resistance in pancreatic neuroendocrine tumours can be overcome with novel PI3K-AKT-mTOR inhibitors , 2016, British Journal of Cancer.

[7]  James C Yao,et al.  Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study , 2016, The Lancet.

[8]  A. Colao,et al.  Predictive factors of response to mTOR inhibitors in neuroendocrine tumours. , 2016, Endocrine-related cancer.

[9]  E. Krenning,et al.  ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site , 2016, Neuroendocrinology.

[10]  R. Thakker,et al.  Challenges and controversies in management of pancreatic neuroendocrine tumours in patients with MEN1. , 2015, The lancet. Diabetes & endocrinology.

[11]  D. Castellano,et al.  Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: a retrospective cross-sectional analysis , 2015, BMC Cancer.

[12]  K. Haridas,et al.  Everolimus plus octreotide long-acting repeatable in advanced neuroendocrine tumors in the routine tertiary cancer care setting: An Indian experience. , 2015, Indian journal of cancer.

[13]  J. Hainsworth,et al.  Impact of Previous Somatostatin Analogue Use on the Activity of Everolimus in Patients with Advanced Neuroendocrine Tumors: Analysis from the Phase III RADIANT-2 Trial , 2015, Neuroendocrinology.

[14]  M. Broder,et al.  Appropriateness of systemic treatments in unresectable metastatic well-differentiated pancreatic neuroendocrine tumors. , 2015, World journal of gastroenterology.

[15]  E. Van Cutsem,et al.  Impact of Prior Chemotherapy Use on the Efficacy of Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors , 2015, Pancreas.

[16]  F. D. De Braud,et al.  Real-world study of everolimus in advanced progressive neuroendocrine tumors. , 2014, The oncologist.

[17]  Bingya Liu,et al.  KRAS and DAXX/ATRX Gene Mutations Are Correlated with the Clinicopathological Features, Advanced Diseases, and Poor Prognosis in Chinese Patients with Pancreatic Neuroendocrine Tumors , 2014, International journal of biological sciences.

[18]  S. Ricci,et al.  Everolimus in combination with octreotide long‐acting repeatable in a first‐line setting for patients with neuroendocrine tumors: An ITMO group study , 2014, Cancer.

[19]  Z. Gabriel,et al.  A systematic review of non-surgical treatments for pancreatic neuroendocrine tumours. , 2014, Cancer treatment reviews.

[20]  M. Höpfner,et al.  Clinically detected gastroenteropancreatic neuroendocrine tumors are on the rise: epidemiological changes in Germany. , 2013, World journal of gastroenterology.

[21]  G. Kaltsas,et al.  Safety and efficacy of everolimus in gastrointestinal and pancreatic neuroendocrine tumors after (177)Lu-octreotate. , 2013, Endocrine-related cancer.

[22]  Yulian Wu,et al.  Surgical treatment of pancreatic islet cell tumor: report of 44 cases. , 2013, Hepato-gastroenterology.

[23]  D. Bentrem,et al.  Predicting aggressive behavior in nonfunctioning pancreatic neuroendocrine tumors. , 2013, Surgery.

[24]  E. Baudin,et al.  Efficacy of everolimus in patients with metastatic insulinoma and refractory hypoglycemia. , 2013, European journal of endocrinology.

[25]  D. Metz,et al.  Consensus guidelines for the management and treatment of neuroendocrine tumors. , 2013, Pancreas.

[26]  Chun‐Chieh Wu,et al.  The Epidemiology of Neuroendocrine Tumors in Taiwan: A Nation-Wide Cancer Registry-Based Study , 2013, PloS one.

[27]  J. C. Ferrer-García,et al.  Management of malignant insulinoma , 2013, Clinical and Translational Oncology.

[28]  H. Burris,et al.  Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway , 2013, Cancer Chemotherapy and Pharmacology.

[29]  U. Knigge,et al.  Surgery for GEP-NETs. , 2012, Best practice & research. Clinical gastroenterology.

[30]  R. Jensen,et al.  Pancreatic neuroendocrine tumors: clinical features, diagnosis and medical treatment: advances. , 2012, Best practice & research. Clinical gastroenterology.

[31]  M. Fassan,et al.  Pathology - grading and staging of GEP-NETs. , 2012, Best practice & research. Clinical gastroenterology.

[32]  K. Öberg,et al.  Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[33]  J. Furuse,et al.  Everolimus for Advanced Pancreatic Neuroendocrine Tumours: A Subgroup Analysis Evaluating Japanese Patients in the RADIANT-3 Trial , 2012, Japanese journal of clinical oncology.

[34]  A. Scarpa,et al.  Malignant pancreatic neuroendocrine tumour: lymph node ratio and Ki67 are predictors of recurrence after curative resections. , 2012, European journal of cancer.

[35]  G. Mills,et al.  PIK3CA/PTEN Mutations and Akt Activation As Markers of Sensitivity to Allosteric mTOR Inhibitors , 2012, Clinical Cancer Research.

[36]  E. Baudin,et al.  ENETS Consensus Guidelines for the Management of Patients with Liver and Other Distant Metastases from Neuroendocrine Neoplasms of Foregut, Midgut, Hindgut, and Unknown Primary , 2011, Neuroendocrinology.

[37]  M. Falconi,et al.  ENETS Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Neoplasms of the Digestive System: Well-Differentiated Pancreatic Non-Functioning Tumors , 2011, Neuroendocrinology.

[38]  J. Ji,et al.  mTOR activation in well differentiated pancreatic neuroendocrine tumors: a retrospective study on 34 cases. , 2011, Hepato-gastroenterology.

[39]  E. D. de Vries,et al.  Everolimus induces rapid plasma glucose normalization in insulinoma patients by effects on tumor as well as normal tissues. , 2011, The oncologist.

[40]  E. Van Cutsem,et al.  Everolimus in patients with advanced pancreatic neuroendocrine tumors (pNET): Impact of somatostatin analog use on progression-free survival in the RADIANT-3 trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  Michael A. Choti,et al.  DAXX/ATRX, MEN1, and mTOR Pathway Genes Are Frequently Altered in Pancreatic Neuroendocrine Tumors , 2011, Science.

[42]  I. Modlin,et al.  The epidemiology of gastroenteropancreatic neuroendocrine tumors. , 2011, Endocrinology and metabolism clinics of North America.

[43]  Y. Bang,et al.  Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. , 2011, The New England journal of medicine.

[44]  D. Coppola,et al.  First‐line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas , 2011, Cancer.

[45]  D. Coppola,et al.  Activation of the serine/theronine protein kinase Akt in enteropancreatic neuroendocrine tumors. , 2010, Anticancer research.

[46]  J. Tabernero,et al.  Targeting the PI3K/Akt/mTOR Pathway – Beyond Rapalogs , 2010, Oncotarget.

[47]  Francesca Molinari,et al.  Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. , 2010, The Journal of clinical investigation.

[48]  R. Jensen,et al.  NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. , 2010, Pancreas.

[49]  G. Åkerström,et al.  Neuroendocrine gastroenteropancreatic tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[50]  David Cella,et al.  Health-Related Quality of Life of Patients With Neuroendocrine Tumor Compared to the United States General Population , 2010 .

[51]  C. Croce,et al.  Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  G. Petersen,et al.  Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[53]  K. Hess,et al.  Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  Manal M. Hassan,et al.  One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  M. Korbonits,et al.  Octreotide and the mTOR Inhibitor RAD001 (Everolimus) Block Proliferation and Interact with the Akt-mTOR-p70S6K Pathway in a Neuro-Endocrine Tumour Cell Line , 2007, Neuroendocrinology.

[56]  A. Tanaka.  [A receptor for the immunosuppressant FK506 is a cis-trans peptidyl-prolyl isomerase]. , 2007, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme.

[57]  B. Skogseid,et al.  Temozolomide as Monotherapy Is Effective in Treatment of Advanced Malignant Neuroendocrine Tumors , 2007, Clinical Cancer Research.

[58]  D. Sabatini,et al.  Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. , 2007, Blood.

[59]  S. Brand,et al.  The Novel mTOR Inhibitor RAD001 (Everolimus) Induces Antiproliferative Effects in Human Pancreatic Neuroendocrine Tumor Cells , 2007, Neuroendocrinology.

[60]  M. Hall,et al.  TOR Signaling in Growth and Metabolism , 2006, Cell.

[61]  Gordon B Mills,et al.  mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. , 2006, Cancer research.

[62]  J. Testa,et al.  Perturbations of the AKT signaling pathway in human cancer , 2005, Oncogene.

[63]  E. Raymond,et al.  mTOR-targeted therapy of cancer with rapamycin derivatives. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[64]  M. Oshimura,et al.  PI3K-Akt pathway: Its functions and alterations in human cancer , 2004, Apoptosis.

[65]  R. Loewith,et al.  Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive , 2004, Nature Cell Biology.

[66]  A. Hoeflich,et al.  Insulin-like growth factor-I is an autocrine regulator of chromogranin A secretion and growth in human neuroendocrine tumor cells. , 2000, Cancer research.

[67]  Paul Tempst,et al.  RAFT1: A mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs , 1994, Cell.

[68]  J. Kunz,et al.  Target of rapamycin in yeast, TOR2, is an essential phosphatidylinositol kinase homolog required for G1 progression , 1993, Cell.

[69]  J. Heitman,et al.  Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast , 1991, Science.

[70]  Nolan H. Sigal,et al.  A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin , 1989, Nature.

[71]  C. Polychronakos,et al.  Somatostatin analogue SMS 201-995 reduces serum IGF-I levels in patients with neoplasms potentially dependent on IGF-I. , 1989, Anticancer research.

[72]  R. Schilsky,et al.  Recommendations for management of patients with neuroendocrine liver metastases. , 2014, The Lancet. Oncology.

[73]  T. Hobday,et al.  Impact of Prior Chemothe rapy Use on the Efficacy of Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors A Subgroup Analysis of the Phase III RADIANT-3 Trial , 2014 .

[74]  R. Pearson.  Everolimus for Advanced Pancreatic Neuroendocrine Tumors , 2011 .

[75]  A. Rosenberg,et al.  Glycemic Control in Patients with Insulinoma Treated with Everolimus , 2009 .